Halozyme Therapeutics (HALO) Deferred Taxes (2012 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Deferred Taxes of -$3.4 million for Q1 2026, down 219.94% year-over-year from $2.9 million in Q1 2025, and down 120.44% quarter-over-quarter from $16.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Deferred Taxes (2012 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Deferred Taxes for 10 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes fell 219.94% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$6.9 million (down 291.32% YoY), while the FY2025 annual figure was -$634000.0, down 19.17% from the prior year.
- Deferred Taxes fell to -$3.4 million in Q1 2026 per HALO's latest filing, from $16.8 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $16.8 million in Q4 2025 and bottomed at -$27.4 million in Q3 2025.
- Historically, Deferred Taxes has averaged -$4.7 million across 5 years, with a median of -$3.9 million in 2023.
- On a YoY basis, Deferred Taxes climbed as much as 321.38% in 2025 and fell as far as 9267.81% in 2025.
- Halozyme Therapeutics' Deferred Taxes stood at -$14.7 million in 2022, then jumped by 35.79% to -$9.4 million in 2023, then surged by 262.28% to $15.3 million in 2024, then climbed by 9.65% to $16.8 million in 2025, then sank by 120.44% to -$3.4 million in 2026.
- Business Quant data shows HALO's Deferred Taxes at -$3.4 million in Q1 2026, $16.8 million in Q4 2025, and -$27.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | -907,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -907,000.00 |
| Mar 31, 2026 | -3.43 Mn |
| Dec 31, 2025 | 16.77 Mn |
| Sep 30, 2025 | -27.35 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 15.29 Mn |
| Sep 30, 2024 | -292,000.00 |
| Jun 30, 2024 | -14.24 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -9.42 Mn |
| Sep 30, 2023 | -9.70 Mn |
| Jun 30, 2023 | -11.51 Mn |
| Mar 31, 2023 | -3.87 Mn |
| Dec 31, 2022 | -14.68 Mn |
| Sep 30, 2022 | -25.70 Mn |
| Jun 30, 2022 | 13.30 Mn |
| Mar 31, 2022 | -12.93 Mn |
| Dec 31, 2021 | 12.95 Mn |
| Sep 30, 2021 | 142.48 Mn |